Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.

MLA

Singer, Barry A., et al. “Diroximel Fumarate in Patients with Relapsing–remitting Multiple Sclerosis: Final Safety and Efficacy Results from the Phase 3 EVOLVE-MS-1 Study.” Multiple Sclerosis Journal, vol. 29, no. 14, Dec. 2023, pp. 1795–807. EBSCOhost, https://doi.org/10.1177/13524585231205708.

APA

Singer, B. A., Arnold, D. L., Drulovic, J., Freedman, M. S., Gold, R., Gudesblatt, M., Jasinska, E., LaGanke, C. C., Naismith, R. T., Negroski, D., Oh, J., Hernandez Perez, M. A., Selmaj, K., Then Bergh, F., Wundes, A., Ziemssen, T., Castro-Borrero, W., Chen, H., Levin, S., & Scaramozza, M. (2023). Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Multiple Sclerosis Journal, 29(14), 1795–1807. https://doi.org/10.1177/13524585231205708

Chicago

Singer, Barry A, Douglas L Arnold, Jelena Drulovic, Mark S Freedman, Ralf Gold, Mark Gudesblatt, Elzbieta Jasinska, et al. 2023. “Diroximel Fumarate in Patients with Relapsing–remitting Multiple Sclerosis: Final Safety and Efficacy Results from the Phase 3 EVOLVE-MS-1 Study.” Multiple Sclerosis Journal 29 (14): 1795–1807. doi:10.1177/13524585231205708.